Loading clinical trials...

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.

NCT00337662•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.
•Patients must have experienced an exacerbation of their illness within the previous 2 weeks.
•Patients in whom a switch to another antipsychotic medication is acutely indicated.

Exclusion Criteria

•Patients who are deemed nonresponsive to risperidone or olanzapine.
•Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.
•Patients having received olanzapine or risperidone in the past 30 days.
•Treatment with clozapine within 1 year prior to Visit 1.
•Diagnosis of substance-induced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).
•A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.

Locations (34)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Little Rock, Arkansas, United States

Escondido, California, United States

Garden Grove, California, United States

Glendale, California, United States

National City, California, United States

Orange, California, United States

San Diego, California, United States

Santa Ana, California, United States

Washington D.C., District of Columbia, United States

Fort Lauderdale, Florida, United States

Key Dates

Start Date

May 1, 2006

Primary Completion Date

December 1, 2007

Completion Date

December 1, 2007

Last Updated

February 17, 2010

Enrollment

628

ACTUAL participants

Conditions

SchizophreniaSchizoaffective DisorderSchizophreniform Disorder

Interventions

olanzapine

DRUG

risperidone

DRUG

risperidone

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia